{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:49:44Z","timestamp":1790232584427,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is no consensus on the standard treatment of gastric mucosa\u2010associated lymphoid tissue (<jats:styled-content style=\"fixed-case\">MALT<\/jats:styled-content>) lymphoma for <jats:italic>Helicobacter pylori<\/jats:italic>\u2010negative patients and for patients with persistent disease despite <jats:italic>H. pylori<\/jats:italic> eradication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the comparative efficacy and safety of alkylating agents and rituximab alone or in combination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this monocentric retrospective study, which included 106 patients who had not been previously treated with anti\u2010cancer agents, we evaluated the efficacy and safety of oral alkylating agents monotherapy (<jats:italic>n<\/jats:italic>\u00a0=\u00a048), rituximab monotherapy (<jats:italic>n<\/jats:italic>\u00a0=\u00a028) and the therapy combining both drugs (<jats:italic>n<\/jats:italic>\u00a0=\u00a030). Evaluations were performed at weeks 6 (W6), 25 (W25), and 52 (W52) and after 2\u00a0years (W104).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After a median follow\u2010up period of 4.9\u00a0years (range 0.4\u201317.2\u00a0years), complete remission and overall response were significantly higher in patients in the combination therapy group at W104 (92% and 100% respectively) compared with patients treated with alkylating agents alone (66% and 68%) and rituximab alone (64% and 73%). The 5\u2010year progression\u2010free survival probabilities were 68%, 70% and 89% in patients treated with alkylating agents alone, rituximab alone and combination therapy respectively. Haematological adverse events were reported in 32 (30%) patients (mostly grade 1) and were more frequent in the two groups receiving alkylating agents (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.05 and <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). No toxicity\u2010related death was reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The use of anti\u2010cancer systemic therapy is safe and efficient in gastric <jats:styled-content style=\"fixed-case\">MALT<\/jats:styled-content> lymphoma. In this retrospective study, the combination of rituximab plus chlorambucil seems more efficient than rituximab or alkylating agents alone. Rituximab has a better safety profile than regimens containing alkylating agents.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.12635","type":"journal-article","created":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T02:35:27Z","timestamp":1390876527000},"page":"619-628","source":"Crossref","is-referenced-by-count":23,"title":["Rituximab, alkylating agents or combination therapy for gastric mucosa\u2010associated lymphoid tissue lymphoma: a monocentric non\u2010randomised observational study"],"prefix":"10.1111","volume":"39","author":[{"given":"A.","family":"Amiot","sequence":"first","affiliation":[{"name":"Department of Gastroenterology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"},{"name":"Department of Pathology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"},{"name":"Lymphoid Malignancies Unit Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00e9vy","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Copie\u2010Bergman","sequence":"additional","affiliation":[{"name":"Department of Pathology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"},{"name":"Faculty of Medicine University of Paris Est Creteil Cr\u00e9teil France"},{"name":"LIC, Laboratoire d'Investigation Clinique EA 4393 Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dupuis","sequence":"additional","affiliation":[{"name":"Unit U955 INSERM IMRB Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Szablewski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Paris Est Creteil Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Le Baleur","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Baia","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Paris Est Creteil Cr\u00e9teil France"},{"name":"LIC, Laboratoire d'Investigation Clinique EA 4393 Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Belhadj","sequence":"additional","affiliation":[{"name":"Unit U955 INSERM IMRB Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sobhani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"},{"name":"Department of Pathology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"},{"name":"Lymphoid Malignancies Unit Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Leroy","sequence":"additional","affiliation":[{"name":"Department of Pathology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"},{"name":"Faculty of Medicine University of Paris Est Creteil Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Haioun","sequence":"additional","affiliation":[{"name":"Department of Pathology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"},{"name":"LIC, Laboratoire d'Investigation Clinique EA 4393 Cr\u00e9teil France"},{"name":"Unit U955 INSERM IMRB Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u2010C.","family":"Delchier","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"},{"name":"Department of Pathology Albert Chenevier\u2010Henri Mondor Hospital Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"232","volume-title":"Non\u2010Hodgkin Lymphomas","author":"Zucca E","year":"2010"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.307"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04839.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300495"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq182"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2524"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05460.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3502"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200412000-00003"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.660"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.825"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403501"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.33047"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3496"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.128"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.729832"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6272"},{"key":"e_1_2_7_19_1","first-page":"218","article-title":"Clinical staging classification of non\u2010Hodgkin's lymphomas (author's transl)","volume":"153","author":"Musshoff K","year":"1977","journal-title":"Strahlentherapie"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(97)70120-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0369-8114(01)00209-7"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903431820"},{"key":"e_1_2_7_24_1","unstructured":"National Cancer Institute.Common terminology criteria for adverse events version 3.0 (CTCAE). Available at:http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf;2006."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.11.1656"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12078"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/9780203091753-13"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.224949"},{"key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","article-title":"The apoptosis inhibitor gene API2 and a novel 18q gene, MLT are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa\u2010associated lymphoid tissue lymphomas","volume":"93","author":"Dierlamm J","year":"1999","journal-title":"Blood"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12635","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:48:27Z","timestamp":1696528107000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/apt.12635"],"URL":"https:\/\/doi.org\/10.1111\/apt.12635","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,27]]}}}